A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Grants and Contracts Details

StatusActive
Effective start/end date11/20/208/16/25

Funding

  • Mirati Therapeutics Incorporated: $239,814.00